[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Two new classes of anticoagulants are actually developed which would change in the near future our strategies for the prevention and the treatment of venous thromboembolic events. These two classes are the anti-factor Xa and anti-factor IIa (direct antithrombin) agents. Among the anti factor Xa, the pentasaccharides are initiating their clinical use. Fondaparinux is a synthetic form of the natural pentasaccharide, its pharmacokinetics allows one s.c. administration/24 hours. It is active in prevention and treatment of venous thromboembolic and coronary thrombotic events. A modified form (idraparinux) whose pharmacokinetics allows one administration only once a week should have the same type of efficacy. Among direct antithrombin agents, hirudin and derivatives have been developed in the past decade with a limited use due to several drawback. More recently synthetic direct antithrombins modified to allow oral route have been developed, the most advanced in development, melagatran, is active in the prevention and treatment of venous thromboembolic and coronary thrombotic events. It could allow (if confirmed by clinical trials) a complete oral treatment of deep vein thrombosis without any biological monitoring. Melagatran is also active in the prevention of arterial thromboembolic events on atrial fibrillation. But other molecular forms of synthetic orally active direct antithrombin are also in development. Besides these important changes in our therapeutics which should appear in a near future, molecules aimed at other target are also tested: the most advanced are those antagonizing the initial phase of tissue factor activation of factor VII but other strategies are being tested such as stimulation of fibrinolysis. These new drugs at our disposal to treat venous thromboembolism should modify completely our handling of the patients. But additionally the numerous clinical trials necessary to prove the efficacy of the drugs, modify our understanding in the implication of the coagulation and in the physiopathogeny of thrombotic events.
Drouet
Ludovic
L
Service d'Angio-Hématologie, Hôpital Lariboisière, 2 rue A. Paré-75010 Paris. ludovic.drouet@lrb.ap-hop-paris.fr
D000284:Administration, Oral; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D002986:Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000517:prevention & control; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006801:Humans; D009985:Orthopedics; D011134:Polysaccharides / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011355:Prodrugs; D011516:Prothrombin / Q000037:antagonists & inhibitors; D012106:Research; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy*
D001384:Azetidines; D001596:Benzylamines; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D011134:Polysaccharides; D011355:Prodrugs; C109573:melagatran; C426686:ximelagatran; D011516:Prothrombin; C025337:Factor IIa; D013917:Thrombin; D000077425:Fondaparinux; D005998:Glycine